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Summary
We report gene localization in a family with a benign
autosomal dominant familial periodic fever (FPF) syn-
drome characterized by recurrent fever associated with
abdominal pain. The clinical features are similar to the
disorder previously described as familial Hibernian fe-
ver, and they differ from familial Mediterranean fever
(FMF) in that FPF episodes usually do not respond to
colchicine and FPF is not associated with amyloidosis.
Frequent recombination with the markerD16S2622, !1
Mb from FMF, at 16p13.3, excluded allelism between
these clinically similar conditions. Subsequently, a sem-
iautomated genome search detected linkage of FMF to
a cluster of markers at 12p13, with a multipoint LOD
score of 6.14 at D12S356. If penetrance of 90% is as-
sumed, the FPF gene maps to a 19-cM interval between
D12S314 and D12S364; however, if complete pene-
trance is assumed, then FPF maps to a 9-cM region
between D12S314 and D12S1695. This interval in-
cludes the dentatorubropallidoluysian atrophy locus,
which, with FPF, gave a maximum two-point LOD score
of 3.7 at a recombination fraction of 0. This is the first
of the periodic-fever genes, other than FMF, to be
mapped. Positional candidate genes may now be selected
for mutation analysis to determine the molecular basis
for FPF. Together with the recent identification of the
defective gene in FMF, identification of a gene for FPF
might provide new insights into the regulation of in-
flammatory responses.
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Introduction
The heritable periodic-fever syndromes are a heteroge-
neous group of rare disorders in which recurrent fever,
abdominal pain, and polyserositis are the primary fea-
tures. Two autosomal recessive (AR) disorders, familial
Mediterranean fever (FMF; MIM 249100) and hyper-
immunoglobulinemia D and periodic fever (hyper-IgD
syndrome, or periodic fever Dutch type; MIM 260920)
have been well characterized clinically. A number of fam-
ilies with autosomal dominant (AD) clinical variants
have also been described; these variants include Hiber-
nian fever (MIM 142680; Williamson et al. 1982;
McDermott et al. 1997), FMF-like syndrome with amy-
loidosis (MIM 134610; Gertz et al. 1987), periodic fever
(MIM 170300; Bouroncle and Doan 1957), and others
(Bergman and Warmenius 1968; Reich and Franklin
1970; Hawle et al. 1989; Karenko et al. 1992; Yuval et
al. 1995; Mache et al. 1996). The molecular basis has
been determined only for FMF (French FMF Consortium
1997; International FMF Consortium 1997). Allelism
between FMF and periodic fever Dutch type has been
excluded by recombination (Drenth et al. 1994; Livneh
et al. 1997).
We report gene localization in an Australian family,
of Scottish descent, that segregates an AD familial pe-
riodic fever (FPF) resembling Hibernian fever (William-
son et al. 1982; McDermott et al. 1997). The locations
for FPF (12p13) and FMF (16p13.3) will enable inves-
tigation of allelism with the remaining AD and AR clin-
ical variants of periodic fever. The positional candidate
approach can potentially lead to identification of the
gene responsible for FPF in this family.
Patients, Material, and Methods
Clinical Features
The portion of the pedigree relevant to the linkage
study is shown in figure 1. Affected family members
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Figure 1 Pedigree of the family with AD FPF and marker haplotypes from the linked region of chromosome 12. Affected family members
share the same marker alleles for D12S356, D12S1695, D12S77, and D12S89. The unaffected family member, 006, in the lowest generation,
suggests a smaller gene localization, between D12S314 and D12S1695, if 100% penetrance is assumed.
typically manifest symptoms by age 15 years—most by
age 10 years. The youngest family member (006) is cur-
rently asymptomatic at age 9 years. Fevers are high
(40C) in most affected family members.
The disorder in this family is characterized by episodic
attacks of fever and abdominal pain with onset during
early childhood or adolescence. The episodes vary in
frequency, generally occurring 3–6 mo apart, but may
occur as often as every few weeks or as far apart as 10
years. Episodes generally decrease in frequency, with age.
The duration of symptoms ranges from days to weeks
but, with treatment, can be shortened to 2–3 d. Abdom-
inal symptoms include anorexia, constipation, and col-
icky abdominal pain, but vomiting is unusual; clinical
examination reveals mild abdominal distension and per-
itonism. Other common symptoms include myalgia, ar-
thralgia, and pleuritic pain. Occasional symptoms in-
clude testicular pain and urticarial skin lesions. No
patients have mucosal abnormalities or lymphadeno-
pathy. The fever is unresponsive to paracetamol or as-
pirin. In most family members, there has been no re-
sponse to colchicine, but moderate doses of oral steroids
have led to resolution of symptoms within 24–72 h. One
patient reports rapid improvement with indomethacin.
The family, scattered through various country towns
in Australia, has not had consistent medical investigation
or treatment. At least three individuals have undergone
laparotomy, with or without appendectomy, during
acute attacks. Several patients have had markedly ele-
vated erythrocyte sedimentation rates, moderate leu-
kocytosis, and moderate thrombocytosis recorded dur-
ing episodes. One child had had a single elevated IgD
level (between attacks, when asymptomatic), which was
normal on repeat testing. This child and three other af-
fected family members had similar mild elevations of
IgM, and one had a normal IgD level; no others have
yet been tested.
No family member is known to have developed amy-
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Table 1
Pairwise LOD Scores between FPF and Markers on Chromosomes 16 and 12
CHROMOSOME
AND MARKER
LOD SCORE AT RECOMBINATION FRACTION OF
Zmax vmax.0 .01 .05 .1 .2 .3 .4
Chromosome 16:
D16S523 9.67 3.59 2.07 1.42 .80 .44 .17
D16S2622 10.93 3.54 1.96 1.23 .55 .21 .15
Chromosome 12:
D12S352 5.12 1.31 .61 .35 .16 .08 .02
D12S314 .24 2.48 2.82 2.67 2.01 1.22 .49 2.82 .05
D12S356 2.40 2.34 2.09 1.78 1.18 .64 .23 2.40 .00
D12S1695 3.14 3.10 2.90 2.62 1.97 1.29 .61 3.14 .00
D12S77 3.98 3.92 3.65 3.27 2.39 1.44 .55 3.98 .00
D12S89 3.58 3.50 3.19 2.79 2.00 1.21 .49 3.58 .00
D12S364 2.83 .38 1.00 1.12 .95 .60 .25 1.12 .01
DRPLA 3.70 3.62 3.31 2.90 2.09 1.28 .53 3.70 .00
NOTE.—Relative position of DRPLA is not known.
loidosis. Individual 3.4 died of renal failure at age 70
years, her son (007) had “Bright’s disease” at age 15
years and required dialysis for renal failure during mid-
dle age, and his son (009) had an episode of hematuria,
diagnosed as nephritis, at age 2 years. He had a rectal
biopsy at age 20 years, which showed no amyloid. In-
dividual 5.1 died from colonic cancer. Although amy-
loidosis was not detected, it is possible that FPF and
FMF-like syndrome with amyloidosis are the same
disorder. We plan to prepare a separate, detailed clinical
report after further investigation of available family
members.
Genotyping
Venous blood was obtained after informed consent,
and DNA was isolated by standard phenol/chloroform
extraction. Manual genotyping of the microsatellite
markers D16S523 and DRPLA was carried out as de-
scribed elsewhere (Phillips et al. 1995). Semiautomated
genotyping was carried out as described elsewhere (Saar
et al. 1997), by use of an ABI 377 sequencer and GE-
NESCAN 2.0 and GENOTYPER V1.1 software. Gen-
otypes were checked for Mendelian segregation, by use
of LINKRUN (T. F. Wienker, personal communication).
Linkage Analysis
Penetrance was conservatively set at 90%. The feas-
ibility of the linkage study was explored by use of SLINK
(Weeks et al. 1990). Two-point LOD scores were com-
puted by the LINKAGE package (Lathrop and Lalouel
1984), and the exclusion map was displayed, for each
chromosome, by use of LODVIEW EXCEL V5.0 (Hil-
debrandt et al. 1993). Multipoint analysis (four-point
disease locus and three marker loci) was carried out by
use of VITESSE (O’Connell and Weeks 1995). Two-
point and multipoint analyses assumed equal marker-
allele frequencies. Haplotyping was carried out by CRI-
MAP V2.41, with the option CHROMPIC (Green et al.
1990). The pedigree, with haplotypes, was drawn by
CYRILLIC.
Results
The FPF gene, segregating in the pedigree shown in
figure 1, was first excluded from the FMF region at
16p13.3 (table 1). The marker D16S523 is !3 cM from
FMF, and the marker D16S2622 is !1 Mb from FMF.
Although both markers are centromeric to FMF, FPF is
excluded from the 5 cM on either side of both markers
and is clearly not allelic with FMF.
SLINK simulation confirmed that detection of linkage
by genome search was achievable for this family; how-
ever, because of the absence of key family members, an
informative marker might need to be close to the FPF
gene to detect linkage. A semiautomated genomewide
search for linkage was initiated, at 330-marker density.
When 236 markers had been genotyped, no evidence
could be found for linkage to chromosomes 1–11, 13,
or 15–22. However, two-point LOD scores from the
subterminal region of the p arm of chromosome 12 (ta-
ble 1) showed linkage, with a maximum LOD score
(Zmax) of 3.98 at a maximum recombination fraction (v)
of 0 for D12S77. The closest recombinants involving
affected family members were at D12S314 distally and
at D12S364 proximally, which limits the FPF gene lo-
calization to an interval of 19 cM.
Multipoint analysis (fig. 2) gave a multipoint LOD
score of 6.14 at D12S356 (four-point analysis with FPF,
D12S356, D12S1695, and D12S77). This confirmed the
likely location of FPF to the 19-cM interval between
D12S314 and D12S364. From the marker haplotype
segregating with FPF (fig. 1), it can be seen that the
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Figure 2 Multipoint LOD scores, computed by VITESSE, giving a peak LOD score of 6.14 at D12S356. (The discrepancies in the heights
of LOD scores arise from different informativeness of each set of three markers—the maximum practical number of markers for analysis of
this pedigree—with large numbers of family members who have not been genotyped).
unaffected individual (006) sharing part of the affected
haplotype has the potential to reduce the localization to
a 9-cM interval betweenD12S314 andD12S1695,when
this individual reaches the age at which penetrance of
100% can be assumed. At present, she is almost 9 years
old; if she carries the FPF gene, she would be expected
to show symptoms by age 15 years.
The 12p13.31 region is known to contain the gene
for dentatorubropallidoluysian atrophy (DRPLA). The
FPF family was genotyped for the polymorphic CAG-
trinucleotide repeat, which, when unstable, causes
DRPLA. Two-point analysis gave a Zmax of 3.70 at
, which indicates thatDRPLA and FPF are likelyv  0max
to map to the same 19-cM interval between D12S314
and D12S364. Whether DRPLA and FPF map within
the same 9-cM interval between D12S314 and
D12S1695 will depend on whether individual 006 de-
velops symptoms of FPF. If she remains asymptomatic,
both DRPLA and FPF are likely to map within the same
9-cM interval between D12S314 and D12S1695. Con-
versely, if she becomes symptomatic, the location of FPF
(but not DRPLA) will move to the adjacent segment,
between D12S1695 and D12S364.
Discussion
The features of various FPF disorders are summarized
in table 2; however, for more-detailed comparisons, see
the work of Livneh et al. (1997) and McDermott et al.
(1997). Although the familial disorder described in the
present study resembles Hibernian fever (Williamson et
al. 1982; McDermott et al. 1997), allelism to the peri-
odic-fever syndromes other than FMF has not been ex-
cluded. Haplotype analysis of a distant lineage related
to this family could lead to significant reduction of the
regional localization of the FPF gene. Such an analysis
for AR FMF (Levy et al. 1996; French FMF Consortium
1996) led to diagnosis, based on linkage disequilibrium
(Dupont et al. 1997), and to ultimate identification of
the defective gene (French FMF Consortium 1997; In-
ternational FMF Consortium 1997). Alternatively, now
that a gene localization has been established, localization
may be narrowed by analysis of additional families with
this AD condition.
Antonarakis (1994) suggested increasing the efficiency
of genome searches by concentrating first on gene-rich
regions of the genome. Inglehearn (1997) subsequently
presented two sets of markers for selective screening of
regions rich in expressed sequence tags. Whereas set B
(25 markers) contained none from chromosome 12, set
A (40 markers) included D12S361, D12S90, and
D12S84. Of these markers, the closest to the FPF re-
gional localization is D12S361, which is ∼30 cM prox-
imal to the FPF region (Dib et al. 1996). In this instance,
directed genome screening, as suggested by Antonarakis
(1994) and Inglehearn (1997), would not have led to
more-rapid chromosomal assignment. This result does
indicate, however, that the FPF gene does not reside in
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Table 2
Comparison between Clinical Forms of FPF
Present Family Hibernian Fever
FMF-like Syndrome
with Amyloidosis FMF Hyper-IgD
Inheritance AD AD AD AR AR
Feature:
Age at onset (years) 2–15 5–20 !10 !20 !1 (70%)
Abdominal pain     
Myalgia   ?  
Arthralgia     
Skin lesions  Urticaria, chest  Painful ery-
thema arms,
trunk, legs
 Erythema around
joints
 Erysipelas-like
lesions below
knees
 Erysipelas-like
lesions below
knees
Lymphadenopathy     
Amyloid  Reported in one
patient
  
Elevated serum IgD   ?  
Elevated acute-phase
reactants
    
Response to:
Colchicine     
Steroid     
NSAI   ? ? 
NOTE.—NSAI  Nonsteroidal anti-inflammatory agents; a plus sign () indicates presence; a minus sign () indicates absence; a question
mark indicates unknown; and a plus-or-minus sign () indicates occasional reports.
a gene-rich region, which may be advantageous for gene
identification (Inglehearn 1997).
The localization of an AD FPF syndrome to 12p13.3
provides the basis for testing unmapped periodic-fever
syndromes, for allelism to the disorder described and
mapped in the present study. Allelism between periodic
fever Dutch type and FMF was excluded in this way
(Drenth et al. 1994), as was allelism between FMF and
the disorder described in the present study (table 1), by
use of the marker D16S523, !3 cM from FMF (French
FMF Consortium 1996), and the marker D16S2622, !1
Mb from FMF (Sood et al. 1997). The pattern of in-
heritance of the family in this study is AD, and the pat-
tern of inheritance in FMF is AR. Defects within the
same gene are only rarely known to cause either AR or
AD inheritance of the same disorder (Christiano et al.
1996).
Linkage data from a disorder as rare as the one de-
scribed here are unable to provide a gene localization
with the precision necessary to allow initiation of po-
sitional cloning. The positional candidate approach may
be useful in this circumstance, especially when the FPF
gene maps to a relatively gene-poor region. The signif-
icance of gene identification for FMF (French FMF Con-
sortium 1997; International FMF Consortium 1997) is
that any gene product related to pyrin, coded by a gene
mapping to 12p13, represents a strong candidate for
FPF. Similarly, members of this gene family represent
strong candidate loci for other unmapped periodic-fever
syndromes.
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